3.1.7 The patient must be able to provide informed 
consent. 
3.2 Criteria for patient ineligibility. 
3.2.1 Patients with active autoimmune disease. 
3.2.2 Patients who have a positive antibody to HIV. 
3.2.3 Patients with active hepatitis, chronic or 
acute. 
3.2.4 Patients with diabetes mellitis who are not 
controlled by medical treatment. 
3.2.5 Psychiatric illness which makes compliance to 
the clinical protocol unmanageable. 
3.2.6 Patients on high dose glucocorticosteroids . 
3.2.7 Patients who undergo an alternative mode of 
anti-cancer treatment will not be accepted 
within 4 weeks of the last treatment. 
[406] 
Recombinant DNA Research, Volume 15 
